Pharmacology Biochemical Pharmacology
Mendelian Randomisation Links Higher Plasma Asparagine to Lower Osteoarthritis Risk; Supplement Protects Cartilage in Mice
- Mendelian randomisation tied higher plasma asparagine to reduced osteoarthritis risk.
- In IL-1β-stimulated chondrocytes, asparagine limited ROS, lipid peroxidation and matrix loss while raising SLC7A11 and GPX4; the p53 activator Nutlin-3 partly reversed this.
- In the DMM mouse model it reduced cartilage degeneration and subchondral bone erosion.
Pairing human genetic evidence with a mechanistic rescue experiment is the right shape of validation. But the causal MR link doesn't tell us whether supplemented asparagine reaches joint tissue at the concentrations used in vitro, and no dose-exposure data are reported; I'd check joint levels and a delayed-start regimen before taking it further.
Paper: Biochemical Pharmacology ↗ L-asparagine alleviates osteoarthritis via inhibiting chondrocyte ferroptosis through the p53/SLC7A11/GPX4 pathway